"Trojan Horse" Tested in EGFR-Amplified Glioblastoma

Ariela Katz
Published: Thursday, Jul 06, 2017
Dr. Martin J. Van Den Bent

Martin J. Van Den Bent, MD

Investigators are seeking to determine whether the addition of ABT-414, an antibody–drug conjugate, to concomitant radiotherapy and temozolomide will improve the survival of patients with newly diagnosed glioblastoma multiforme (GBM) with epidermal growth factor receptor (EGFR) amplification.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Overcoming Clinical Inertia in Glioblastoma Multiforme: The Experts Weigh-In on Recent Data Sets and Next Steps to Move the Field ForwardDec 21, 20191.5
Publication Bottom Border
Border Publication
x